19331
014
ACC0010.1177/2048872613519331European Heart Journal: Acute Cardiovascular CareSciahbasi et al.
EUROPEAN SOCIETY OF CARDIOLOGY ®
Original scientific paper
Bivalirudin or heparin in primary angioplasty performed through the transradial approach: results from a multicentre registry
European Heart Journal: Acute Cardiovascular Care 2014, Vol. 3(3) 268–274 © The European Society of Cardiology 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/2048872613519331 acc.sagepub.com
Alessandro Sciahbasi1, Stefano Rigattieri1, Bernardo Cortese2, Flavia Belloni3, Carmelo Russo1, Alessandro Ferraironi3, Maurizio Tespili4, Chiara Angeletti4, Roberto Ricci3, Francesco Bondanini1 and Francesco Rocco Pugliese1
Abstract Background: Data on the effect of bivalirudin therapy in primary percutaneous coronary interventions (PCI) performed through the transradial approach are limited. The aim of our study was to evaluate bleeding complications and clinical outcomes in primary PCI performed through the transradial approach with bivalirudin therapy. Methods: We retrospectively evaluated primary PCI performed through the transradial approach from January 2008 to June 2013. Patients were divided in two groups according to the use (group 1) or not (group 2) of bivalirudin. The primary end points were major bleedings and major adverse cardiac events (MACE) within 30 days. Results: During the 5 years analysed, 1009 patients underwent primary PCI through the transradial approach: 154 patients were treated with bivalirudin (males 79%, age 65±14 years) and 855 with heparin (males 82%, 63±12 years). In group 1, the use of glycoprotein IIb/IIIa inhibitors was only 4%, compared to 55% (p
014
ACC0010.1177/2048872613519331European Heart Journal: Acute Cardiovascular CareSciahbasi et al.
EUROPEAN SOCIETY OF CARDIOLOGY ®
Original scientific paper
Bivalirudin or heparin in primary angioplasty performed through the transradial approach: results from a multicentre registry
European Heart Journal: Acute Cardiovascular Care 2014, Vol. 3(3) 268–274 © The European Society of Cardiology 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/2048872613519331 acc.sagepub.com
Alessandro Sciahbasi1, Stefano Rigattieri1, Bernardo Cortese2, Flavia Belloni3, Carmelo Russo1, Alessandro Ferraironi3, Maurizio Tespili4, Chiara Angeletti4, Roberto Ricci3, Francesco Bondanini1 and Francesco Rocco Pugliese1
Abstract Background: Data on the effect of bivalirudin therapy in primary percutaneous coronary interventions (PCI) performed through the transradial approach are limited. The aim of our study was to evaluate bleeding complications and clinical outcomes in primary PCI performed through the transradial approach with bivalirudin therapy. Methods: We retrospectively evaluated primary PCI performed through the transradial approach from January 2008 to June 2013. Patients were divided in two groups according to the use (group 1) or not (group 2) of bivalirudin. The primary end points were major bleedings and major adverse cardiac events (MACE) within 30 days. Results: During the 5 years analysed, 1009 patients underwent primary PCI through the transradial approach: 154 patients were treated with bivalirudin (males 79%, age 65±14 years) and 855 with heparin (males 82%, 63±12 years). In group 1, the use of glycoprotein IIb/IIIa inhibitors was only 4%, compared to 55% (p
